Becton, Dickinson and Company

NYSE BDX

Becton, Dickinson and Company Price to Book Ratio (P/B) on January 14, 2025: 2.04

Becton, Dickinson and Company Price to Book Ratio (P/B) is 2.04 on January 14, 2025, a -22.87% change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.
  • Becton, Dickinson and Company 52-week high Price to Book Ratio (P/B) is 2.78 on March 28, 2024, which is 36.53% above the current Price to Book Ratio (P/B).
  • Becton, Dickinson and Company 52-week low Price to Book Ratio (P/B) is 1.90 on December 06, 2024, which is -6.98% below the current Price to Book Ratio (P/B).
  • Becton, Dickinson and Company average Price to Book Ratio (P/B) for the last 52 weeks is 2.47.
Key data
Date Price to Book Ratio (P/B) Dividend Yield Free Cash Flow Yield Price to Earnings Ratio (P/E)
Market news
Loading...
NYSE: BDX

Becton, Dickinson and Company

CEO Mr. Thomas E. Polen Jr.
IPO Date Feb. 21, 1973
Location United States
Headquarters 1 Becton Drive
Employees 70,000
Sector Health Care
Industries
Description

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.

Similar companies

HAE

Haemonetics Corporation

USD 79.96

0.69%

RGEN

Repligen Corporation

USD 156.55

-1.19%

COO

The Cooper Companies, Inc.

USD 89.11

-2.38%

TFX

Teleflex Incorporated

USD 179.17

0.35%

WST

West Pharmaceutical Services, Inc.

USD 328.96

-3.13%

RMD

ResMed Inc.

USD 228.83

-0.62%

XRAY

DENTSPLY SIRONA Inc.

USD 18.06

-3.21%

ICUI

ICU Medical, Inc.

USD 161.08

1.85%

HOLX

Hologic, Inc.

USD 70.20

-0.13%

ANGO

AngioDynamics, Inc.

USD 11.80

-5.30%

StockViz Staff

January 15, 2025

Any question? Send us an email